COO Cooper Companies (The)

Q2 2025 10-Q

Filed: May 30, 2025Period ending Apr 30, 2025

Health Care

Ophthalmic GoodsSEC EDGAR

Cooper Companies (The) (COO) 10-Q quarterly report for Q2 2025, filed with SEC EDGAR on May 30, 2025 for the fiscal period ending Apr 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q2 2025 10-Q

Risk Factors

• No newly added risk factors disclosed in this quarter's 10-Q versus prior 10-K
• Most materially updated risk: increased focus on silicone hydrogel and single-use contact lenses due to market shift and growth in preferred modalities

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$1.0B

Net Income

$88M

Gross Margin

67.8%

Operating Margin

18.4%

Net Margin

8.7%

Source: XBRL data from Cooper Companies (The) Q2 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Cooper Companies (The) Quarterly Reports

Q1 2026 10-Q

Q3 2025 10-Q

Q1 2025 10-Q

Get deeper insights on Cooper Companies (The)

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.